AWAP IV constitutes the C-terminal domain of the larger 81 kDa protein AWAK [Avian WAP (whey acidic protein) domain-and Kunitz domain-containing], which is predicted, through conserved domain database searching, to contain at least four WAP domains and one Kunitz domain. RT (reverse transcription)-PCR analyses revealed mRNA transcripts encoding AWAP IV in the small intestinal and kidney tissues of 5-day-old Salmonella-infected chicks. Time-kill antimicrobial assays using rAWAP IV (recombinant AWAP IV) cell lysate indicated antimicrobial activity against Gram-positive and Gram-negative bacteria including Salmonella, Streptococcus and Staphylococcus spp. In addition, permeabilization of the outer membrane of Salmonella, as shown by the NPN (N-phenyl-1-naphthylamine) fluorescent probe assay, supported the ability of rAWAP IV to disrupt prokaryotic membranes. WAP domains can function as inhibitors of serine protease activity, and the microbial serine proteases subtilisin and proteinase K were inhibited by rAWAP IV cell lysate. However, at comparable concentrations, no significant inhibition of the mammalian serine protease elastase was observed. The combined broad-spectrum antibacterial and anti-protease activities of AWAP IV suggest a novel role in the avian innate defence mechanisms operating against microbial infection.
Introduction
The innate immune system of higher eukaryotes provides the first line of defence against pathogenic invasion of the host, and includes the synthesis of small (1-10 kDa), structurally diverse AMPs (antimicrobial peptides). Such peptides, with a broad spectrum of activity against Gram-negative and Grampositive bacteria, fungi and some enveloped viruses, have been isolated from the tissues and cells of many species including vertebrates, non-vertebrates and plants. In general, AMPs function by targeting and disrupting microbial membranes and this is mediated by a combination of the peptide size, charge, amino acid composition and amphipathicity. In addition, some AMPs are internalized and function by interference with microbial cell metabolism (reviewed in [1] ).
As well as their role in limiting microbial numbers, AMPs contribute to the defence of the host in a number of ways, including the promotion of wound repair [1] . In mammals, such activities have been reported for a group of molecules characterized by cysteine-rich or WAP (whey acidic proteins) domains and known as the four-disulphide-core proteins [2] . WAP domains comprise approx. 50 amino acids and include eight highly conserved cysteine residues which fold to form a tightly packed structure containing four disulphide bonds. Antibacterial proteins containing WAP domains have been described and include the human SLPI (secretory leucocyte proteinase inhibitor) [3, 4] . SLPI, synthesized and secreted at mucosal sites in response to inflammation and injury, has activity against Gram-positive and Gram-negative bacteria [4, 8] and is an effective anti-inflammatory agent neutralizing the activity of proteases released by host neutrophils during inflammation [5] .
We recently described, using reverse-phase HPLC and an antimicrobial assay system, the isolation from chick intestinal mucosa of an avian peptide with antimicrobial activity against Salmonella. This peptide was subsequently identified as the C-terminal WAP domain of a novel multidomain avian protein, AWAK (Avian WAP domain-and Kunitz domaincontaining), which has no known mammalian homologue [6] . In the present paper, we describe the further in vitro characterization of the C-terminal WAP domain, AWAP IV.
The structure of AWAP IV
In silico analysis of the predicted AWAP IV primary amino acid sequence (RVGVCPIPRVAWGTCLDLCSFD-EECPWGQKCCSNGCGHICMPASLEE) suggests a nonglobular peptide, containing a single α-helix (http://www. predictprotein.org). However, the presence of eight cysteine residues (shown in boldface) conserved amongst members of the WAP family indicates a tightly packed structure mediated through the formation of four disulphide bonds in a predicted 1-4, 2-3, 5-8 and 6-7 configuration.
Expression, antimicrobial activity and haemolysis
RT (reverse transcription)-PCR analysis localized the expression of transcripts encoding the AWAP IV domain to epithelial tissues, including small intestine and kidney, excised from chicks infected with Salmonella. Epithelial tissues are the first point of attack for many pathogens, and the synthesis of AMPs in such tissues is a common mechanism of innate host defence. The expression of AWAP IV in the chick intestine, the purification of the peptide from intestinal mucosa and its antibacterial properties [6] all suggest a role for the peptide, and predictably the parent AWAK molecule, in protecting the avian gut from microbial attack. Moreover, the identification of a putative NF-κB (nuclear factor κB) transcription factor-binding site in the promoter region of the AWAK gene also provides a potential signalling mechanism by which transcription is activated in response to microbial infection.
AWAP IV was initially identified by its antimicrobial activity against the mutant Salmonella enterica serovar Typhimurium strain phoP [6] . To investigate further the antimicrobial properties of AWAP IV, a 170 bp cDNA sequence encoding the four-disulphide core domain was cloned into pRSETA and hyperexpressed in Escherichia coli, using the Origami B::pLysS strain to facilitate disulphide bond formation [7] . Using rAWAP IV (recombinant AWAP IV) lysate (30 µM) and a time-kill assay, we observed the killing of an array of Gram-negative and Gram-positive bacterial strains (Figure 1) , suggesting that the C-terminal or AWAP IV domain has broad-spectrum antibacterial activity. Moreover, at this concentration, bacterial killing was not associated with the haemolysis of mammalian erythrocytes. Thus, in vitro, the AWAP IV peptide showed selectivity for bacterial over mammalian cells.
Mechanism of action
The mechanism by which AWAP IV causes bacterial killing is not known. To investigate whether this involves outer membrane permeabilization, we employed the NPN (Nphenyl-1-naphthylamine) probe that fluoresces strongly in the hydrophobic environment of a damaged membrane [8] .
Using Salmonella as the target organism, we observed a change in fluorescence in the presence of AWAP IV (20 µg), consistent with disruption of the outer membrane. However, while the increase in fluorescence observed with Salmonella enterica serovar Typhimurium occurred within seconds, that with Salmonella enterica serovar Enteriditis was much slower (minutes). These results are consistent with the findings of the time-kill assay, which indicated Salmonella enterica serovar Enteriditis to be more resistant to AWAP IV killing, and probably reflected differences in the membrane compositions of the different Salmonella species.
Anti-protease selectivity
Members of the four-disulphide core family, including ovulatory proteins from trout and eNAP-2 (equine neutrophil antimicrobial peptide 2) from equine neutrophils, have been shown to function as inhibitors of serine proteases [9, 10] . We investigated the ability of the rAWAP IV lysate to inhibit the proteolytic activity of several proteases including elastase (from pig leucocytes), subtilisin (from Bacillus) and proteinase K (from Tritirachium). At a concentration consistent with antimicrobial activity (30 µM), the rAWAP IV lysate did not affect the activity of the mammalian serine protease elastase but significantly inhibited (P < 0.05) the activities of the microbial serine proteases subtilisin and proteinase K (Figure 2 ). Thus the ability of AWAP IV to inhibit proteases, often used by microbes to increase virulence, may help in protecting the host from potentially pathogenic microbes.
Collectively, the expression of AWAP IV in epithelial tissues, its broad-spectrum antibacterial activity and selective inhibition of microbial proteases suggest a role for the peptide in avian innate immunity. The role of the other AWAK domains, and the interactions of AWAP IV with these domains, remains to be determined.
